December 03, 2012
Endo Pharmaceuticals Inc. on Friday urged a judge to force the U.S. Food and Drug Administration to determine whether the drugmaker voluntarily yanked the original version of its Opana ER painkiller from the market over tampering and abuse concerns and to suspend approval of nontamper-resistant generic versions.